Monday, 26 August 2019

Nanjing King-Friend to invest $95M in Meitheal Pharma

12 August 2019 | News

Meitheal Pharmaceuticals to Serve as Exclusive US Commercialization Arm in Partnership

image credit- shuttershock.com

image credit- shuttershock.com

Meitheal Pharmaceuticals, a fully integrated generic injectables company based in Chicago, Illinois has announced that Hong Kong King-Friend Industrial Company, a wholly-owned subsidiary of China-based manufacturer Nanjing King-Friend Biochemical Pharmaceutical Company (NKF), has agreed to take an increased stake in the business for $95 million. Upon close of the transaction, which is anticipated in the fourth quarter of 2019, NKF will have a majority share of ownership in Meitheal.

Meitheal primarily specializes in the development, manufacture, procurement, and sale of generic injectable pharmaceuticals, with 12 FDA-approved products covering indications for anti-infective, oncolytic and intensive care. Furthermore, Meitheal has an expanding product portfolio and robust pipeline, including single and multi-dose vials, ready-to-use prefilled syringes and premixed bags.

As of the end of June 2019, Meitheal had 49 products in the research and development phase, 24 products were under review by the US Food and Drug Administration (FDA), and 8 products were planned to be launched in 2019.

Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account



Podcast

 

Survey Box

Will APAC lead the way for innovation in the field of precision medicine?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls